Julie Grossman, MD
Surgical Oncology · Miami, FLNPI 1114215365
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,836 of the $4,411 with a category attached, or 87.0%. Boehringer Ingelheim accounts for 87.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $3,944 and has fallen 96.8% since, to $126 in 2025.
Across 11 payments — averaging $401.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$4K
- Dilon Technologies, Inc.$311
- Pacira Pharmaceuticals Incorporated$108
- Stryker$83
- Genentech USA, Inc.$25
- Bayer$18
- plus $30 from 2 others
What the payments were for
- Speaking & faculty fees$3,83687%
- Food & beverage$57513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $3,836 |
| Dilon Technologies, Inc. | 2 | $311 |
| Pacira Pharmaceuticals Incorporated | 1 | $108 |
| Stryker | 3 | $83 |
| Genentech USA, Inc. | 1 | $25 |
| Bayer | 1 | $18 |
| Solventum Corporation | 1 | $18 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HemoBlast Bellows$311
- EXPAREL$108
How this compares
$4,411 in reported general payments places this provider in the 65th percentile of 133 surgical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Miami
- Neha GoelMiami$200K
- Horacio AsbunMiami$161K
- Mehran HabibiMiami$73K
- Kristin RojasMiami$57K
- Amit KhithaniMiami$32K
- Geoffrey YoungMiami$22K
- Nipun MerchantMiami$11K
- Meghan CrawleyMiami$5K
- Levan TsamalaidzeMiami$4K
- Ahkeel AllenMiami$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.